Excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) is a critical gene in the Nucleotide excision repair pathway. A growing list of reports links cisplatin, carboplatin, and oxaliplatin based chemotherapy resistance to ERCC1 expression levels in several tumors. ERCC1 has been shown to be an important marker to predict responsiveness to cisplatin-based chemotherapy. Low ERCC1 gene expression correlates with prolonged survival after cisplatin-based chemotherapy. The ERCC1 (19q13) FISH probe has been optimized to detect copy numbers of the ERCC1 gene region at 19q13. The ZNF443 (19p13) probe is included to facilitate chromosome identification.
References: Olaussen et al, 2006, N. Engl. J. Med. 335; 983-991. Ceppi et al, 2006, Ann. Oncol. 17; 1818-1825.
Due to manufacturing & supply chain issues, this product is currently unavailable. You may place your order and it will be fulfilled when the product is back in stock. For more help, please reach out to customer service at +1 844 534 2262 or email@example.com
Product is limited in stock
Product availability is limited, but products are in continuous production. Your order will be processed as normal and may take additional days to ship.